CytoMed Therapeutics Limited (GDTC)
NASDAQ:GDTC
Want to see GDTC full AI Analyst Report?
GDTC Stock Chart & Stats
$1.39
-$0.41(-13.85%)
At close: 4:00 PM EST
$1.39
-$0.41(-13.85%)
Day’s Range― - ―
52-Week Range$0.68 - $3.68
Previous CloseN/A
Volume107.31K
Average Volume (3M)166.79K
Market Cap
$13.49M
Enterprise Value$12.23M
Total Cash (Recent Filing)$2.10M
Total Debt (Recent Filing)$482.56K
Price to Earnings (P/E)―
Beta0.06
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)N/A
Shares Outstanding11,832,835
10 Day Avg. Volume104,297
30 Day Avg. Volume166,789
Financial Highlights & Ratios
PEG Ratio-0.10
Price to Book (P/B)3.07
Price to Sales (P/S)62.86
P/FCF Ratio-4.56
Enterprise Value/Market Cap0.91
Enterprise Value/Revenue27.95
Enterprise Value/Gross Profit-40.14
Enterprise Value/Ebitda-2.86
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Improved Leverage And EquityCapitalization has improved meaningfully in recent years, with debt reduced and equity sizable versus assets. That stronger balance sheet lowers near-term refinancing risk, supports ongoing trial activity and expansion plans, and provides financial flexibility to fund operations while clinical programs progress.
Owned Production PropertiesA tangible asset base of five production properties and low-cost regional infrastructure is a durable operational advantage. It reduces fixed operating costs, provides collateral for financing or monetization, and underpins manufacturing capacity and regional expansion without immediate heavy capex.
Progressing Clinical Pipeline & PartnershipsConcrete pipeline progress — Phase I CAR‑T dosing, multi-site gamma delta T cell trial, and a collaboration/preclinical work with MD Anderson — strengthens scientific credibility and long-term upside. Advancing trials builds durable intellectual and regulatory assets that can create future commercial opportunities.
Bears Say
Weak Cash Generation / Intensified Cash BurnOperating and free cash flow have been negative throughout the period and worsened in 2025, forcing reliance on external funding. Limited internal cash generation constrains runway for multi-site trials and expansion, increases financing need, and raises the probability of dilutive raises or strategic trade-offs.
Persistent Operating Losses And Negative MarginsSustained operating and net losses with deteriorating gross margins and a negative gross profit in 2025 indicate weak unit economics. Over the medium term this undermines the firm's ability to self-finance growth, compresses returns, and increases dependency on external capital or restructuring.
Share Issuance Authority / Dilution RiskManagement has sought shareholder approval to issue new shares and instruments, creating a structural pathway for dilution to fund operations. While this provides financing flexibility, it also raises long-term dilution and governance risk that can materially affect shareholder value and ownership concentration.
CytoMed Therapeutics Limited News
GDTC FAQ
What was CytoMed Therapeutics Limited’s price range in the past 12 months?
CytoMed Therapeutics Limited lowest stock price was $0.68 and its highest was $3.68 in the past 12 months.
What is CytoMed Therapeutics Limited’s market cap?
CytoMed Therapeutics Limited’s market cap is $13.49M.
When is CytoMed Therapeutics Limited’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were CytoMed Therapeutics Limited’s earnings last quarter?
Currently, no data Available
Is CytoMed Therapeutics Limited overvalued?
According to Wall Street analysts CytoMed Therapeutics Limited’s price is currently Overvalued.
Does CytoMed Therapeutics Limited pay dividends?
CytoMed Therapeutics Limited does not currently pay dividends.
What is CytoMed Therapeutics Limited’s EPS estimate?
CytoMed Therapeutics Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does CytoMed Therapeutics Limited have?
CytoMed Therapeutics Limited has 11,832,835 shares outstanding.
What happened to CytoMed Therapeutics Limited’s price movement after its last earnings report?
Currently, no data Available
Which hedge fund is a major shareholder of CytoMed Therapeutics Limited?
Currently, no hedge funds are holding shares in GDTC
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
CytoMed Therapeutics Limited
CytoMed Therapeutics Limited is a biopharmaceutical company in the pre-clinical development phase, founded in 2018 and based in Singapore. The firm specializes in creating advanced cellular immunotherapies aimed at combating various human malignancies. Its primary investigational product, CTM-N2D, involves cultivated gamma delta T cells that are engineered with a chimeric antigen receptor (CAR) specifically targeting natural killer group 2D ligands, designed to boost their capacity to destroy cancer cells. Beyond its lead candidate, CytoMed is also advancing iPSC-gdNKT, which utilizes induced pluripotent stem cells (iPSCs) to generate a novel hybrid cell combining properties of both gamma delta T cells and natural killer cells. Additionally, the company is developing CTM-GDT, an immunotherapy consisting of expanded gamma delta T cells that leverages their innate, broad-spectrum recognition system to identify and address diverse cancer types.
Technical Analysis
Ownership Overview
33.15% Insiders
0.04% Mutual Funds
0.19% Other Institutional Investors
66.62% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---